Table 2. Background of the Patients.
| Newer AED addition group (n = 23) | Old AED alone group (n = 21) | |
|---|---|---|
| Sex | ||
| Male | 16 (69.6%) | 14 (66.7%) |
| Female | 7 (30.4%) | 7 (33.3%) |
| Age (years) | ||
| Average ± standard deviation | 26.5 ± 7.3 | 29.8 ± 8.3 |
| Maximum | 39 | 45 |
| Minimum | 10 | 12 |
| Median | 27.0 | 30.0 |
| Main disease | ||
| Cerebral palsy | 9 (39.1%) | 14 (66.7%) |
| Hypoxia encephalopathic aftereffects | 3 (13.0%) | 2 (9.5%) |
| Epileptic encephalopathy aftereffects | 3 (13.0%) | 0 |
| Cerebral hemorrhage aftereffects | 2 (8.7%) | 0 |
| Lissencephaly | 2 (8.7%) | 0 |
| CFC syndrome | 0 | 2 (9.5%) |
| Meningitis aftereffects | 1 (4.3%) | 0 |
| Dentatorubral-pallidoluysian atrophy (DRPLA) | 1 (4.3%) | 0 |
| Acute encephalopathic aftereffects | 1 (4.3%) | 0 |
| Theophylline encephalopathic aftereffects | 1 (4.3%) | 0 |
| Arthrogryposis | 0 | 1 (4.8%) |
| Schizencephaly | 0 | 1 (4.8%) |
| Psychomotor retardation | 0 | 1 (4.8%) |
| Renal damage | ||
| Available | 0 | 0 |
| None | 23 | 21 |
| Liver damage | ||
| Available | 0 | 0 |
| None | 23 | 21 |
| Comorbidities* | ||
| Available | 0 | 0 |
| None | 23 | 21 |
| Use of AED† | ||
| Valproate sodium (VPA) | 19 (24.1%) | 15 (40.5%) |
| Phenytoin (PHT) | 6 (7.6%) | 6 (16.2%) |
| Phenobarbital (PB) | 6 (7.6%) | 5 (13.5%) |
| Clonazepam (CZP) | 6 (7.6%) | 0 |
| Carbamazepine (CBZ) | 4 (7.7%) | 6 (16.2%) |
| Zonisamide (ZNS) | 4 (5.1%) | 1 (2.7%) |
| Clobazam (CLB) | 3 (3.8%) | 2 (5.4%) |
| Ethosuximide (ESM) | 2 (2.5%) | 1 (2.7%) |
| Others | 3 (3.8%) | 1 (2.7%) |
| Lamotrigine (LTG) | 11 (13.9%) | 0 |
| Levetiracetam (LEV) | 15 (19.0%) | 0 |
*Hypertension, diabetes, hyperlipidemia, kidney disease, infectious disease. †There is overlap in a value.